Hong Kong has spent the past decade trying to turn laboratory research into products that reach an operating theatre, and robotic surgery is where that effort now shows most. The Standard reported that the Hong Kong Science and Technology Parks Corporation, the statutory body known as HKSTP, is backing two lines of work that put the city near the front of surgical robotics: an artificial intelligence “Co-pilot” for general surgery built by Professor Qi Dou, and a family of orthopaedic robots from Yuanhua Tech. Both were developed in and around the Hong Kong Science Park, and both carry a clear pitch to patients who travel for surgery.
Professor Qi Dou builds an AI co-pilot for surgery
Professor Qi Dou leads a group at the InnoHK Multi-Scale Medical Robotics Center, the publicly funded centre known as the MRC. Her team is building an artificial intelligence co-pilot for general surgery, The Standard reported, a system meant to work alongside the surgeon rather than replace the surgeon. On the current robots a surgeon must drive every movement by hand. Her co-pilot instead takes on set tasks on its own, such as tissue retraction, grasping gauze, clipping vessels and positioning the camera, all on simple voice commands. Its aim is to cut the mental and physical load during long laparoscopic operations.
Dou’s group says it has cleared three technical hurdles, The Standard reported. The system has to generalise across very different patient anatomies, it has to work with the surgical robots already in theatres rather than force new kit, and it has to hand tasks back and forth with the surgeon cleanly. Her group has run live animal trials in the MRC’s hybrid operating rooms, which it uses to move a device from bench to bedside, and it says those trials showed the system was stable and eased the surgeon’s workload. Professor Dou expects clinical use within five years, once the regulators settle how much autonomy an operating robot may hold.
That five-year line is the one to watch. Autonomy in the operating theatre is a genuine world-first regulatory problem, and it sits square on two of the four risks that shadow medical travel: clinical risk and legal redress. A patient who flies in for surgery assisted by a semi-autonomous system needs a clear answer on who is accountable when something goes wrong, the surgeon, the hospital or the maker of the robot. Hong Kong will not win cross-border patients on the technology alone until that answer is written down.
Yuanhua Tech and the KUNWU orthopaedic robot
A second line of work comes from Yuanhua Tech, which runs its head office inside the Hong Kong Science Park. Chief executive Lily Meng wants to make the city a hub for high-end medical technology, The Standard reported, and the company’s flagship is the KUNWU robotic orthopaedic system, billed as a “5-in-1” platform. One unit covers knee, hip, spine and trauma surgery, which the company presents as a global first for that spread of procedures in a single robot. “Our technology is built on entirely self-developed algorithms,” Meng said. That system turns a patient’s CT scan into a 3D surgical plan and works to sub-millimetre accuracy, The Standard reported.
The orthopaedic focus is telling. Joint replacement and spine work are among the specialities that travel best, because they are planned, priced and scheduled weeks ahead, and a patient can fly in for a fixed procedure with a known recovery. A robot that promises tighter accuracy and less soft-tissue damage speaks straight to that patient, since faster recovery is one of the five drivers that move people across borders for care. Those claims still have to be proved in human outcomes rather than in animal trials and CT plans, and that is the ground on which any orthopaedic tourism pitch will stand or fall.
Yuanhua Tech is also working on active capsule endoscopy. Unlike the passive pill cameras a patient simply swallows, these capsules can be steered from outside the body, The Standard reported, guided through the digestive tract to find lesions within minutes and even to drop medicine at a chosen spot. If it holds up in use, it is a real step in diagnostics and in gastroenterology, and it widens the range of care Hong Kong can offer beyond the operating theatre.
HKSTP and the INNOPOLE build-out
None of this scales without somewhere to make it. HKSTP is speeding up INNOPOLE, The Standard reported, a hub inside the larger San Tin Technopole, built around an “AI plus” approach with health technology as a main focus. The plan is to give high-growth firms the heavy computing they need, including high-performance and edge computing, so that a device proven in the Science Park can be produced at scale rather than stall after the first trial.
This is the part that matters most for a destination, and it is the part that is easiest to overlook. Robotics headlines are cheap; a working chain from research to a regulated, manufactured, reimbursable device is not. HKSTP is trying to build that chain in one place, from the MRC’s translational work through Yuanhua Tech’s production to the wider frontier firms INNOPOLE is meant to house. If it works, the city keeps its homegrown innovation instead of exporting the good ideas and importing the finished machines.
What robotic surgery means for Hong Kong as a destination
The medical-tourism read here should stay measured. On our own model, medical tourism sits at the clinical end of health tourism, judged on outcomes and safety, and a strong medtech base is an input to that, not the finished product. Hong Kong is building genuine capability in surgical robotics, and that capability can pull in patients who want the newest and most accurate care. It will only convert, though, if the city pairs the technology with internationally accredited hospitals, clear pricing, interpreters and aftercare, and a written line of accountability for machine-assisted surgery.
The specific work now falls to the hospitals and operators, not the labs. HKSTP has done the harder half by funding the research and the factory floor. The people who run Hong Kong’s clinical services have to turn robots proven in animal trials into published human outcomes, and then package those outcomes into pathways an overseas patient can actually book. The robotics story is real. Whether it becomes a medical tourism story is a separate question, and it will be answered in operating theatres and discharge notes rather than in the laboratory.
